GlobeNewswire — Private Companies·US·
Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial
First-in-class oral ERAP1 inhibitor GRWD0715 dosed in first axSpA participants; clean SAD safety data and US patent granted
Read releases like this the second they cross the wire.
1,200+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 7-day free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →Shared via PPN World — real-time press release intelligence.